#1 Clinical Trials Search in Europe

Camlipixant

Camlipixant is an investigational drug currently being studied in clinical trials for its potential in treating cough. These trials aim to evaluate the safety, effectiveness, and interactions of Camlipixant with other medications. The studies involve healthy participants and those with specific health conditions to gather comprehensive data on how the drug works in different scenarios.

Table of Contents

What is Camlipixant?

Camlipixant, also known as GSK5464714 or BLU-5937, is a new drug currently being studied for its potential in treating cough[1][2]. It’s important to note that this medication is still in the research phase and is not yet available for general use. Scientists are conducting various studies to understand how well it works and how safe it is for patients.

What Conditions Does Camlipixant Treat?

The primary condition that Camlipixant is being developed to treat is cough[1]. While the exact type of cough isn’t specified in the available information, it’s likely being studied for chronic cough conditions that are difficult to treat with existing medications. Chronic cough is a persistent cough that lasts for several weeks or months and can significantly impact a person’s quality of life.

How Camlipixant Works

While the exact mechanism of action isn’t detailed in the provided information, Camlipixant is likely designed to target specific receptors or pathways in the body that are involved in the cough reflex. By modulating these targets, the drug aims to reduce the frequency and severity of coughing in patients with chronic cough conditions.

Ongoing Research

Several clinical trials are currently underway to study various aspects of Camlipixant:

  • Pharmacokinetics in Hepatic Impairment: One study is looking at how the drug behaves in the bodies of people with liver problems compared to those with normal liver function[1]. This is important because the liver plays a crucial role in processing medications.
  • Food Effect Study: Another trial is investigating how food affects the absorption and processing of Camlipixant in the body[2]. This information will help determine whether the drug should be taken with or without food.
  • Drug Interaction Studies: Researchers are also examining how Camlipixant interacts with other medications such as gemfibrozil, dabigatran etexilate, rifampin, and rabeprazole[3][4]. This is crucial for understanding potential risks when patients are taking multiple medications.

Potential Side Effects

As Camlipixant is still in the research phase, a complete list of side effects is not yet available. However, the clinical trials are closely monitoring for any adverse events, which may include:

  • Changes in vital signs (blood pressure, heart rate, temperature)
  • Abnormalities in blood tests (hematology, clinical chemistry, coagulation)
  • Changes in electrocardiogram (ECG) readings
  • Any other unexpected medical events

It’s important to note that all medications can have side effects, and part of the research process is to identify and understand these potential effects[4].

Drug Interactions

Researchers are specifically studying how Camlipixant interacts with other medications:

  • Gemfibrozil: A medication used to lower cholesterol and triglycerides in the blood.
  • Dabigatran etexilate: An anticoagulant (blood thinner) used to prevent blood clots.
  • Rifampin: An antibiotic used to treat various bacterial infections, including tuberculosis.
  • Rabeprazole: A medication used to reduce stomach acid in conditions like gastroesophageal reflux disease (GERD).

These studies will help doctors understand if Camlipixant can be safely taken with other common medications[3][4].

Special Considerations

The ongoing research is also looking at how Camlipixant affects people with different levels of liver function, from normal to severely impaired[1]. This is important because many medications are processed by the liver, and people with liver problems may need different dosages or may not be able to take certain medications safely.

Additionally, researchers are studying how food affects the absorption of Camlipixant[2]. This will help determine whether the medication should be taken with meals or on an empty stomach for the best effect.

Aspect Details
Drug Name Camlipixant (also known as BLU-5937, GSK5464714)
Primary Condition Cough
Trial Types Phase 1 studies, pharmacokinetic studies, drug-drug interaction studies
Key Measurements AUC, Cmax, Tmax, half-life, clearance, volume of distribution
Safety Assessments Adverse events, vital signs, ECG, laboratory tests
Special Populations Healthy volunteers, participants with hepatic impairment
Interaction Studies Food effect, interactions with gemfibrozil, dabigatran etexilate, rifampin, rabeprazole
Study Designs Open-label, randomized, crossover, fixed-sequence

FAQ

  • What is Camlipixant? Camlipixant is an experimental drug being studied for its potential to treat cough. It's currently undergoing clinical trials to assess its safety and effectiveness.
  • What are the main goals of the Camlipixant clinical trials? The trials aim to evaluate Camlipixant's safety, how it's processed by the body (pharmacokinetics), its effectiveness in treating cough, and how it interacts with other medications.
  • Who can participate in these clinical trials? The trials involve both healthy volunteers and participants with specific conditions, such as hepatic impairment. Eligibility criteria vary for each study, but generally include adults aged 18-75 years.
  • What are some of the things being measured in these trials? Researchers are measuring how Camlipixant is absorbed, distributed, and eliminated from the body. They're also monitoring for any side effects and how the drug interacts with food and other medications.
  • How long do these clinical trials typically last? The duration varies depending on the specific study. Some trials last a few days, while others may extend up to several weeks, with follow-up periods to monitor long-term effects.

Ongoing Clinical Trials on Camlipixant

  • Study on the Effectiveness and Safety of Camlipixant for Adults with Refractory or Unexplained Chronic Cough

    Not yet recruiting

    1 1
    Investigated drugs:
    Czechia Germany Poland Slovakia

  • Study on the Effects of Camlipixant in Adults with Refractory or Unexplained Chronic Cough

    Not recruiting

    1 1
    Investigated drugs:
    Belgium France Hungary The Netherlands Poland Spain

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used to understand how much of the drug is in the body.
  • Cmax: The maximum concentration of a drug in the blood after it's been administered.
  • Hepatic Impairment: A condition where the liver doesn't function as well as it should, which can affect how drugs are processed in the body.
  • Open-label Study: A type of clinical trial where both the researchers and participants know which treatment is being given.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.
  • Drug-drug Interaction: When one drug affects the activity of another drug when both are taken together, potentially changing how either drug works in the body.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Half-life: The time it takes for the amount of a drug in the body to be reduced by half.
  • Washout Period: A period of time during a clinical trial when participants stop taking a medication to allow it to be completely eliminated from their body before starting a new treatment.

References

  1. https://clinicaltrials.gov/study/NCT06222892
  2. https://clinicaltrials.gov/study/NCT06497517
  3. https://clinicaltrials.gov/study/NCT05959447
  4. https://clinicaltrials.gov/study/NCT05899829